21 U.S.C. § 355(a)
-
FDA turns focus on biologics in spate of warning letters
The three letters point to an enforcement posture toward manufacturers marketing biologics derived from human placentas and umbilical cords.
The three letters point to an enforcement posture toward manufacturers marketing biologics derived from human placentas and umbilical cords.